We joined Linda Mileshkin (Peter MacCallum Cancer Centre) following her presentation at ESMO 2019 to discuss the disparities of starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial.
Questions
1. Could you tell us a little about the OUTBACK trial and its findings? (0:06)
2. What was the impact of the delayed start of adjuvant therapy on clinical outcomes? (1:31)
3. What can be done to minimise these disparities? (2:01)
4. What are the key take home messages of your presentation? (2:40)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Linda Mileshkin has nothing to disclose in relation to this video.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
